Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Smoldering Multiple Myeloma × isatuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 13 Recurrence 2 Lymphoma, Non-Hodgkin 2 Hematologic Neoplasms 2 Smoldering Multiple Myeloma 1 Renal Insufficiency 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Natural Killer/T-cell Lymphoma 1 Lymphoma 1 Leukemia, Plasma Cell 1 Hodgkin Disease 1

Interventions

Curcumin 3 Dexamethasone 2 selinexor 1 piperine 1 isatuximab 1 iberdomide 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 daratumumab 1 auricularum 1 Resistance Training 1 Propranolol 1 Probiotics 1 Lenalidomide 1 Docosahexaenoic Acids 1 Diet, Plant-Based 1 Calcium Dobesilate 1 Behavior Therapy 1 Adrenergic beta-Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡